what are the hurdles to using cell of origin in classification to treat dlbcl?
Published 8 years ago • 1.1K plays • Length 20:02Download video MP4
Download video MP3
Similar videos
-
24:06
high risk myeloma: how and should it be treated differently?
-
23:58
double hit lymphoma - what is it and how should we treat it?
-
19:09
treatment for marginal zone lymphoma: should it be different from follicular lymphoma?
-
18:59
how i approach early relapsing follicular lymphoma
-
18:00
how should we manage lymphocyte predominant hodgkin lymphoma?
-
1:00:53
how fast can multiple myeloma progress and what biologically happens when it does?
-
2:25
warning signs of lymphoma
-
4:55
what is multiple myeloma?
-
11:07
key insights: lymphoma
-
7:19
lymphoma – an introduction
-
19:42
t-cell lymphoma
-
7:24
lymphoma: overview of classification
-
19:05
update: relapsed/refractory follicular lymphoma
-
22:53
key insights in lymphoma: from lymphoma & myeloma 2018
-
18:54
how should we treat double hit and double expressor dlbcl?
-
3:53
debunking 5 myths about lymphoma
-
24:24
double-hit dlbcl
-
5:52
what is lymphoma? a medical film explaining the most common type of blood cancer
-
33:05
follicular lymphoma debate: watch and wait or treat immediately?
-
23:28
richter’s syndrome: what are the options?
-
40:06
multiple myeloma: a pathway to better outcomes
-
27:49
hodgkin disease: the past, the present, and the future